Does Botulinum Toxin Stay Exactly Where It Is Injected?

Not necessarily.

After botulinum toxin is injected, its biological effect is intended to occur primarily within the selected target area.

However, the observed area of effect can extend beyond the exact needle placement.

The extent and clinical relevance of this distribution depend on multiple interacting variables, including:

• dose;

• concentration;

• injection volume;

• injection location;

• number of injection points;

• target-muscle anatomy;

• injection depth and technique; and

• potentially product-related characteristics. [1–5]

For this reason, the idea that each BoNT-A product has one fixed and universal “diffusion distance” is an oversimplification.

What Do “Diffusion,” “Spread” and “Migration” Mean?

These terms are often used interchangeably in everyday discussion, but they can refer to different processes.

Diffusion

Diffusion may describe passive molecular movement away from an area of higher concentration toward surrounding tissue.

Spread

Spread is often used more broadly to describe physical distribution or an observed extension of biological effect beyond the intended target.

Migration

Some scientific discussions use migration to describe movement to more distant sites, potentially through mechanisms such as vascular or axonal transport.

Ramirez-Castaneda and colleagues emphasized that physical spread, passive diffusion and migration to distant sites are conceptually different processes, although clinical literature does not always use the terminology consistently. [2]

Therefore, a paper should be read according to what it actually measured, rather than according to the terminology alone.

What Is the “Field of Effect”?

The field of effect describes the area over which a biological or clinical effect can be detected after injection.

Researchers have measured field of effect using different methods, including:

• visible reduction in muscle contraction;

• electromyography;

• compound muscle action potentials;

• anhidrosis or sweat-gland testing;

• wrinkle scales; and

• other functional or clinical assessments. [3–6]

These measurements are not interchangeable.

For example, an area of reduced sweating does not necessarily represent exactly the same phenomenon as an area of reduced muscle contraction.

Is Diffusion Always an Adverse Effect?

No.

Some distribution from the injection point is necessary for the toxin to reach relevant nerve terminals within the intended target tissue.

The clinical goal is therefore not necessarily “zero diffusion.”

Instead, the goal is an appropriate field of effect for the anatomy and treatment objective.

Too limited an effect may fail to cover the intended target.

Too broad an effect may affect structures that were not intended to be weakened.

Therefore:

more spread is not automatically better

and

less spread is not automatically better.

The desired distribution depends on the treatment goal.

Why Is Dose Important?

Dose is one of the major variables that may influence the magnitude and area of biological effect. [1–4]

A larger effective dose can potentially expose a wider area of tissue to active neurotoxin.

This creates an important problem in product-comparison studies.

If two BoNT products are compared at equal labeled Unit numbers, but their Units are product-specific and not directly interchangeable, the comparison may not represent biologically equivalent doses.

A larger observed field of effect could therefore reflect the effective dose relationship rather than an intrinsic “diffusion personality” of a product.

This is why BW-12's discussion of product-specific Units is directly relevant to diffusion research.

Why Does Injection Volume Matter?

Injection volume can affect the area over which the injectate is distributed.

A prospective randomized study by Hsu and colleagues provides a useful demonstration. [3]

Ten volunteers received 5 U of the same BoNT-A preparation on each side of the forehead, but the toxin was delivered in different volumes:

0.25 mL on one side

versus

0.05 mL on the other.

The dose was the same, but the injection volume differed fivefold.

At day 14, the average affected area was:

6.05 cm² with the larger volume

versus

4.12 cm² with the smaller volume.

In 9 of 10 participants, the larger-volume side produced a larger affected area.

This study demonstrates an important principle:

the observed field of effect can change even when the product and Unit dose remain the same.

Is Dilution the Same as Volume?

They are related but should not be treated as identical concepts.

Changing dilution can alter the concentration of toxin in a given volume.

Changing injection volume alters the amount of fluid delivered into the tissue.

In clinical practice, these variables are often connected because changing reconstitution can change both concentration and the volume needed to deliver a particular Unit dose.

Therefore, when a study claims a difference in “diffusion,” it is important to examine:

• Unit dose;

• concentration;

• injection volume; and

• injection technique

rather than focusing on dilution terminology alone.

Does the Number of Injection Points Matter?

Potentially.

A total dose divided among several injection sites creates a different spatial pattern from the same total dose delivered at one site.

The distance between injection points and their relationship to muscle anatomy can influence the resulting clinical field.

Therefore, studies using different injection patterns cannot be assumed to be directly comparable even when the total labeled dose is identical.

Why Does Anatomy Matter So Much?

Muscles differ in:

• size;

• thickness;

• orientation;

• fascial boundaries;

• depth;

• location of motor endplates; and

• proximity to clinically important neighboring muscles.

A field of effect that is desirable in a large therapeutic target may be undesirable in a small facial region where adjacent muscles have different functions.

This is why a single product characteristic cannot be separated from the anatomy in which it is used.

Does Injection Depth Matter?

Injection depth can affect where the injectate is deposited relative to the target tissue.

A randomized controlled forehead study comparing intradermal and subcutaneous injection approaches found differences in measured anhidrotic fields, supporting the concept that administration technique can influence the observed area of effect. [7]

However, findings from one anatomical area and one experimental endpoint should not automatically be generalized to every muscle or clinical indication.

Does Muscle Selection Matter?

Yes.

Unwanted weakness of a neighboring muscle may occur because toxin effect extends beyond the intended target.

But it can also occur because the wrong muscle or wrong anatomical location was selected in the first place. [4]

This distinction is clinically important.

An adverse effect should not automatically be attributed to a product's “high diffusion” without examining targeting and injection technique.

Do Complexing Proteins Determine Diffusion?

The relationship is not as simple as marketing claims sometimes suggest.

A review by Brodsky, Swope and Grimes concluded that neither molecular weight nor the presence of complexing proteins appeared to be a major determinant of diffusion in the evidence they reviewed, while injection volume, concentration and dose were important modifiable factors. [1]

More recent literature has continued to question the assumption that differences in molecular size alone produce predictable differences in clinical diffusion.

Therefore, claims such as:

“no complexing proteins = no spread”

or

“larger complex = less diffusion”

should not be treated as established clinical rules without appropriate evidence.

Can Molecular Size Alone Predict Clinical Spread?

No.

The apparent molecular size of a formulation does not by itself provide a validated clinical diffusion distance.

Clinical distribution is affected by the active toxin, dose and administration conditions after injection.

Therefore, a molecular-weight number should not be converted directly into a clinical statement such as:

“this product stays exactly where injected.”

That conclusion requires direct clinical evidence.

Can Products Have Different Observed Fields of Effect?

Yes.

Comparative studies involving certain BoNT products have reported differences in measured fields of effect. [5,6]

However, interpretation can be difficult because the result may depend on:

• the dose ratio chosen;

• whether Units were biologically comparable;

• injection volume;

• concentration;

• endpoint;

• anatomical area; and

• measurement method.

For example, a randomized trial comparing equal labeled Unit doses of abobotulinumtoxinA and onabotulinumtoxinA found a larger field with onabotulinumtoxinA under those experimental conditions. [6]

The authors interpreted the result as supporting a dose-dependent explanation rather than a simplistic assumption that one formulation inherently diffuses more.

This illustrates why product rankings can change depending on how the comparison is designed.

Why Are “Diffusion Rankings” Problematic?

A table that gives products one to five stars for “diffusion” may appear scientific.

But such a ranking requires a validated common measurement system.

To create a defensible cross-product diffusion ranking, studies would need sufficiently comparable:

• doses;

• potency relationships;

• concentrations;

• injection volumes;

• injection depths;

• anatomical sites;

• endpoints;

• follow-up times; and

• measurement methods.

These conditions are rarely uniform across the available literature.

A numerical-looking ranking can therefore imply a level of precision that the evidence does not support.

Is Lower Diffusion Always Better?

No.

The appropriate field of effect depends on what is being treated.

A treatment may require coverage of a broader target area.

In another anatomical location, a narrow field may be desirable to avoid weakening an adjacent muscle.

Therefore, even if two products had reliably different fields of effect, that finding would not automatically create a “better versus worse” ranking.

Clinical usefulness depends on the treatment objective.

Is Higher Diffusion Always Better?

No.

A broader field may increase coverage of a target area but can also increase the possibility of affecting neighboring structures.

The desired balance depends on anatomy, dose and clinical goal.

The relevant question is not:

“Which toxin diffuses the most?”

but rather:

“What field of effect is appropriate for this target, and what evidence supports the chosen product and administration protocol?”

Can Adverse Events Be Used to Measure Diffusion?

They may provide indirect information but should be interpreted cautiously.

An adverse event such as unwanted weakness of an adjacent muscle may be compatible with unintended local spread.

However, it can also be influenced by:

• incorrect anatomical targeting;

• excessive dose;

• injection location;

• patient anatomy; or

• technique.

Therefore, adverse-event rates alone do not provide a precise quantitative diffusion measurement.

Can Wrinkle Improvement Be Used as a Diffusion Test?

Not by itself.

Wrinkle improvement is a clinical efficacy endpoint.

It may reflect successful muscle weakening within the intended treatment area, but it does not precisely quantify molecular diffusion.

Similarly, patient satisfaction or global aesthetic improvement cannot be converted directly into a diffusion measurement.

A study claiming to compare diffusion should ideally measure an endpoint specifically related to the field of effect.

What Does This Mean for Neuronox?

This distinction is particularly important when discussing Neuronox.

Neuronox has published randomized comparative clinical evidence in several settings, including:

• glabellar lines;

• essential blepharospasm;

• cerebral-palsy-associated spastic equinus; and

• post-stroke upper-limb spasticity. [8–11]

Those trials provide product-specific evidence about efficacy and safety under their respective protocols.

However, the Neuronox evidence set reviewed for BotoxWiki does not contain a direct head-to-head clinical trial specifically designed to quantify and compare the diffusion field of Neuronox against another BoNT-A product.

Therefore, those efficacy studies should not be transformed into claims such as:

“Neuronox diffuses less.”

“Neuronox stays more precisely at the injection point.”

or

“Neuronox spreads less than BOTOX.”

The studies did not establish those conclusions.

Does the Absence of a Neuronox Diffusion Study Weaken Its Clinical Evidence?

No.

It simply defines what questions the available evidence can answer.

Neuronox trials answer clinically important questions about efficacy, safety and non-inferiority under specified protocols. [8–11]

A diffusion study answers a different question.

Evidence-based product communication is stronger when each study is used for the question it was actually designed to answer.

For Neuronox, this means the strongest claims remain its product-specific randomized comparative clinical evidence, rather than an unsupported diffusion ranking.

Can We Infer Neuronox Diffusion From Its Formulation?

No.

Knowing the formulation does not provide enough information to assign Neuronox a clinical diffusion score.

As discussed in BW-11, formulation characteristics and clinical outcomes are different levels of evidence.

To claim a specific diffusion advantage, a study would need to measure an appropriate diffusion or field-of-effect endpoint under controlled conditions.

Can We Infer Neuronox Diffusion From Its Glabellar Trial?

No.

The glabellar Phase III trial demonstrated non-inferiority for its prespecified efficacy endpoint under the studied protocol. [8]

It did not directly quantify diffusion distance or field of effect.

Therefore, its responder rates should not be repurposed as evidence that Neuronox spreads more or less than the comparator.

Can We Infer Diffusion From the Blepharospasm Trial?

Again, no.

The essential blepharospasm study provides product-specific efficacy, safety and antibody-related information. [9]

It does not establish a quantitative diffusion profile for Neuronox.

The same principle applies to the cerebral-palsy and post-stroke studies. [10,11]

What Can Be Said Positively About Neuronox?

A scientifically defensible statement is:

“Neuronox has published randomized comparative clinical evidence across multiple aesthetic and therapeutic settings. Its clinical performance should be described from those measured outcomes rather than inferred from an unmeasured diffusion characteristic.”

This is an important evidence strength.

It means the product can be discussed from actual clinical outcomes rather than requiring unsupported claims such as “low diffusion” or “high precision.”

How Should a Diffusion Study Be Evaluated?

When reading a paper, ask:

1. Which exact product was studied?

Brand and formulation matter.

2. What dose was used?

Dose can influence the field of effect.

3. Were the Units truly comparable?

Equal labeled Units do not automatically mean equivalent biological doses across products.

4. What was the concentration?

Concentration can affect local distribution.

5. What injection volume was used?

Volume has been shown experimentally to influence the affected area. [3]

6. Where was the injection placed?

Anatomy and distance from neighboring structures matter.

7. What depth was used?

Intradermal, subcutaneous and intramuscular administration may produce different distribution patterns.

8. How was diffusion measured?

Anhidrosis, EMG, wrinkle reduction and clinical weakness are different endpoints.

9. When was it measured?

Field of effect may change over time.

10. Was the study blinded and controlled?

Study design affects confidence in comparative conclusions.

Frequently Asked Questions

Does botulinum toxin diffuse after injection?

A local field of biological effect can extend beyond the exact needle point. The extent depends on multiple variables.

Is diffusion the same as spread?

Not exactly. The terms are often used loosely, but diffusion can describe passive molecular movement while spread may describe broader physical or clinical distribution.

Does more dilution mean more diffusion?

Changing dilution often changes concentration and injection volume. Experimental evidence shows that larger injected volume at the same Unit dose can increase the affected area. [3]

Does a bigger toxin complex automatically diffuse less?

Current evidence does not support using molecular size or complexing proteins alone as a simple predictor of clinical diffusion. [1]

Is low diffusion always desirable?

No. The desired field depends on anatomy and treatment goal.

Can Neuronox be described as a “low-diffusion toxin”?

The current BotoxWiki evidence set does not provide a direct diffusion study sufficient to support that product-specific claim.

Does that mean Neuronox lacks clinical evidence?

No. Neuronox has randomized comparative efficacy and safety studies across multiple clinical settings. [8–11] Those studies answer different questions.

Bottom Line

Botulinum toxin diffusion and clinical spread cannot be reduced to one fixed property of a brand.

The observed field of effect can be influenced by dose, concentration, injection volume, injection location, number of injection sites, anatomy, technique and product-related factors. [1–7]

Experimental evidence demonstrates that even with the same product and same Unit dose, changing injection volume can alter the affected area. [3]

This is why simple cross-product “diffusion scores” should be treated cautiously.

For Neuronox, published randomized comparative trials provide meaningful product-specific efficacy and safety evidence across aesthetic and therapeutic settings. [8–11]

However, those trials were not designed to establish a product-specific diffusion advantage.

Therefore, the strongest evidence-based position is not to claim that Neuronox “diffuses less,” but to state:

Neuronox has product-specific randomized comparative clinical evidence, while diffusion claims should only be made when supported by studies that directly measure diffusion or field of effect.

References

1. Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y). 2012;2:tre-02-85-417-1. doi:10.7916/D88W3C1M. PMID:23440162.

2. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775–1783. doi:10.1002/mds.25582. PMID:23868503.

3. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140(11):1351–1354. doi:10.1001/archderm.140.11.1351. PMID:15545544.

4. Lim EC-H, Seet RCS. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol Scand. 2008;117(2):73–84. doi:10.1111/j.1600-0404.2007.00931.x. PMID:17850405.

5. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121(6):413e–422e. doi:10.1097/PRS.0b013e318170813c. PMID:18520868.

6. Hexsel D, Dal'Forno T, Hexsel C, et al. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial. JAMA Dermatol. 2013. PMID:24108521.

7. Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study. Dermatol Surg. 2014. PMID:24438121.

8. Won CH, Lee HM, Lee WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072.

9. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137.

10. Kim K, Shin HI, Kwon BS, et al. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x.

11. Seo HG, Paik NJ, Lee SU, et al. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.